UNSPSC 51181611: Azetirelin

This classification denotes a thyrotropin-releasing hormone analogue with the molecular formula C15H20N6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70J5AWG54Q, chemically known as l-prolinamide, n-((4-oxo-2-azetidinyl)carbonyl)-l-histidyl-, (s)- but generally known as azetirelin, which bears US NIH Compound Identifier 65841. Azetirelin most often comes in base and dihydrate forms. European Medicines Agency schedules Azetirelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05653MIG.

UNSPSC 51181611 Azetirelin, a Commodity code, represents pharmaceutical products sourced through multistate cooperative purchasing vehicles that aggregate demand across state agencies, local health departments, and correctional facilities. State and local governments buy azetirelin and similar pharmaceutical compounds as part of formulary management and therapeutic procurement programs, typically through cooperative contracts that establish pricing tiers and supply agreements with authorized wholesalers rather than direct manufacturer purchasing. The issuing bodies are state procurement offices administering multistate purchasing alliances and their member jurisdictions—state departments, counties, municipalities, and institutional buyers including correctional systems and public health agencies that rely on cooperative vehicles to consolidate volume and negotiate standardized pricing for generic pharmaceuticals and over-the-counter products.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. Vendors must supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and demonstrate cGMP certification, DSCSA compliance, and pricing flexibility across flat-price, net-price, and WAC-minus structures. Evaluation weights 75 percent on price competitiveness, with the remaining 25 percent split across fixed pricing, administrative-fee compliance, EDI capability, and data-format requirements. Awarded vendors will be provided to wholesalers by May 15, 2026, with contracts effective July 1, 2026 for a two-year initial term, and vendors must maintain comprehensive insurance including $5 million commercial general liability and $2 million network security and privacy coverage.